Related Experiment Video
Updated: May 5, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
[Diagnosis and therapy of late onset Pompe disease]
A Schüller1, C Kornblum, M Deschauer
1Friedrich-Baur-Institut, Neurologische Klinik, Klinikum der Universität München, Ziemssenstr. 1a, 80336, München, Deutschland.
Abstract:
As Pompe disease glycogen storage disease type 2 with a severely reduced life expectancy is now a treatable disorder, accurate diagnostic procedures and evidence-based indications for therapy are mandatory. We screened the literature for consensus reports and published trial data of late-onset Pompe disease. These data were summarized in a Delphi consensus method approach. The clinical suspicion of late-onset Pompe disease should be substantiated by the validated dry blood spot test measurement for acid α-glucosidase activity. Alternatively, enzyme activity analysis in lymphocytes is also feasible. Glucosidase α gene sequencing for verifying the diagnosis is recommended. A muscle biopsy including measurements of acid α-glucosidase activity and glycogen concentration is warranted for differential diagnosis in selected cases. The confirmed diagnosis should lead to a multidisciplinary treatment approach, possibly including enzyme replacement therapy.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Cardiomyopathy V: Interprofessional Care
Parkinson Disease ll: Pathophysiology
Lysosomal Hydrolases
Chronic Pancreatitis II: Collaborative Care
Assessment:

